- Home
- RNXT vs SLGL Comparison
RNXT vs SLGL Comparison
Compare RNXT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | SLGL |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0M | 247.1M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | RNXT | SLGL |
|---|---|---|
| Price | $1.13 | $68.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 331.0K | 10.5K |
| Earning Date | 03-30-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,000.00 | N/A |
| Revenue This Year | $2,995.35 | N/A |
| Revenue Next Year | $219.61 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.40 |
| 52 Week High | $1.45 | $97.97 |
Technical Indicators
Market Signals| Indicator | RNXT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.75 | 41.76 |
| Support Level | $1.05 | $32.56 |
| Resistance Level | $1.41 | $71.43 |
| Average True Range (ATR) | 0.08 | 11.12 |
| MACD | 0.03 | -2.76 |
| Stochastic Oscillator | 99.97 | 17.76 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.